Long-Term Follow-Up of EBT-101 for HIV
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to monitor the long-term effects of EBT-101, a treatment for HIV. The focus is on observing how participants who received EBT-101 in a previous study are doing over time. This follow-up is crucial for understanding the ongoing impact and safety of the treatment. Those who participated in the original study and received EBT-101 might be suitable candidates for this trial. As a Phase 1 trial, the research focuses on understanding how the treatment works in people.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
Is there any evidence suggesting that EBT-101 is likely to be safe for humans?
Research has shown that EBT-101 has undergone safety testing in earlier studies. In one study, participants with HIV received EBT-101, and it met its main safety goals, indicating it was generally well-tolerated. Reports from that study confirmed that most participants did not experience serious side effects. Some minor side effects occurred, but they were not severe enough to halt the trial. This early evidence suggests EBT-101 might be safe for humans, but further research is necessary to confirm this.12345
Why do researchers think this study treatment might be promising?
EBT-101 is unique because it uses a novel gene-editing approach to target HIV at its genetic source. Unlike standard antiretroviral therapies that aim to suppress the virus, EBT-101 is designed to potentially eliminate it by cutting out sections of the HIV DNA integrated into human cells. Researchers are excited about this treatment because it offers the possibility of a one-time intervention that could lead to long-term remission or even a cure, in contrast to the lifelong daily medications currently required to manage HIV.
What evidence suggests that EBT-101 might be an effective treatment for HIV?
Research has shown that EBT-101, a gene therapy using CRISPR technology, offers promising early results for managing HIV. In one study, a patient maintained virus control for 16 weeks after stopping regular treatment, which exceeded the usual duration. However, for most participants, EBT-101 did not prevent the HIV virus from returning. The therapy has been proven safe, but its ability to completely stop the virus remains under investigation. These early findings suggest potential, but further research is needed to confirm long-term benefits. Participants in this trial will undergo long-term follow-up to evaluate the effects of EBT-101 further.12467
Who Is on the Research Team?
William Kennedy, MD
Principal Investigator
Excision BioTherapeutics
Are You a Good Fit for This Trial?
This trial is for adults with HIV who have previously received the investigational treatment EBT-101 in an earlier study. They must have signed a consent form agreeing to participate and be monitored over time.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Long-Term Follow-Up
Participants will have follow-up visits every six months until Year 5 post EBT-101 administration
Extended Follow-Up
Participants will have annual follow-up visits on the anniversary of EBT-101 administration until study completion
What Are the Treatments Tested in This Trial?
Interventions
- EBT-101
Trial Overview
The focus of this study is on long-term follow-up of patients who were treated with EBT-101, which is a new intervention for HIV. The goal is to observe the extended effects and outcomes after initial treatment.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants who received EBT-101 in a parent study will undergo long term follow up
Find a Clinic Near You
Who Is Running the Clinical Trial?
Excision BioTherapeutics
Lead Sponsor
Citations
1.
excision.bio
excision.bio/news/press-releases/detail/43/excision-biotherapeutics-announces-data-from-the-phase-12Press Releases
EBT-101 successfully met the primary endpoint of safety and secondary endpoint of biodistribution/immunogenicity in a Phase 1/2 study ...
NCT05144386 | Study of EBT-101 in Aviremic HIV-1 ...
This is a FIH, open-label, sequential cohort, single ascending dose (SAD) study of EBT-101 administered IV to aviremic HIV-1 infected adults on stable ART.
The role of genetic diversity, epigenetic regulation, and sex ...
The first-in-human clinical trial of Excision BioTherapeutics' CRISPR-based HIV cure, EBT-101, demonstrated safety but failed to prevent viral ...
4.
aidsmap.com
aidsmap.com/news/may-2024/crispr-gene-therapy-ebt-101-does-not-prevent-hiv-viral-reboundCRISPR gene therapy EBT-101 does not prevent HIV viral ...
One EBT-101 recipient was able to maintain viral suppression for 16 weeks after treatment discontinuation, considerably longer than it typically ...
CRISPR HIV gene therapy disappoints in early study
One EBT-101 recipient was able to maintain viral suppression for four months after treatment discontinuation—considerably longer than it ...
Excision BioTherapeutics initiates Phase 1/2 trial ...
The FIH study is a multicenter, open-label, single ascending dose study designed to evaluate the safety, tolerability and efficacy of EBT-101. The trial is ...
7.
crisprmedicinenews.com
crisprmedicinenews.com/news/excisions-ebt-101-demonstrates-safety-in-clinical-trial-but-does-not-cure-hiv/Excision's EBT-101 Demonstrates Safety in Clinical Trial ...
The objectives of the Phase 1/2 trial are to evaluate the safety and pharmacodynamics of EBT-101 in individuals living with HIV type 1 (HIV-1), ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.